Peptide Inhibitors of the Interaction of the SARS-CoV-2 Receptor-Binding Domain with the ACE2 Cell Receptor

IF 0.6 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY
R. Sh. Bibilashvili, M. V. Sidorova, U. S. Dudkina, M. E. Palkeeva, A. S. Molokoedov, L. I. Kozlovskaya, A. M. Egorov, A. A. Ishmukhametov, E.V. Parfyonova
{"title":"Peptide Inhibitors of the Interaction of the SARS-CoV-2 Receptor-Binding Domain with the ACE2 Cell Receptor","authors":"R. Sh. Bibilashvili,&nbsp;M. V. Sidorova,&nbsp;U. S. Dudkina,&nbsp;M. E. Palkeeva,&nbsp;A. S. Molokoedov,&nbsp;L. I. Kozlovskaya,&nbsp;A. M. Egorov,&nbsp;A. A. Ishmukhametov,&nbsp;E.V. Parfyonova","doi":"10.1134/S199075082104003X","DOIUrl":null,"url":null,"abstract":"<p>Computer simulation has been used to identify peptides that mimic the natural target of the SARS-CoV-2 coronavirus spike (S) protein, the angiotensin-converting enzyme type 2 (ACE2) cell receptor. Based on the structure of the complex of the protein S receptor-binding domain (RBD) and ACE2, the design of chimeric molecules consisting of two 22–23-mer peptides linked to each other by disulfide bonds was carried out. The chimeric molecule X1 was a disulfide dimer, in which terminal cysteine residues in the precursor molecules h1 and h2 were connected by the S-S bond. In the chimeric molecule X2, the disulfide bond was located in the middle of each precursor peptide molecule. The precursors h1 and h2 mimic amino acid sequences of α1- and α2-helices of the ACE2 extracellular peptidase domain, respectively, keeping intact most of the amino acid residues involved in the interaction with RBD. The aim of the work was to evaluate the binding efficiency of chimeric molecules and their constituent peptides with RBD (particularly in dependence of the middle and terminal methods of fixing the initial peptides h1 and h2). The proposed polypeptides and chimeric molecules were synthesized by chemical methods, purified to 95–97% purity, and characterized by HPLC and MALDI-TOF mass spectrometry. Binding of these peptides to the SARS-CoV-2 RBD was evaluated by microthermophoresis with recombinant domains corresponding in sequence to the original Chinese (GenBank ID NC_045512.2) and the British (B. 1.1.7, GISAID EPI_ISL_683466) variants. The original RBD of the Chinese variant bound to three synthesized peptides: linear h2 and both chimeric variants. Chimeric peptides were also bound to the RBD of the British variant. The antiviral activity of the proposed peptides was evaluated in Vero cell line.</p>","PeriodicalId":485,"journal":{"name":"Biochemistry (Moscow), Supplement Series B: Biomedical Chemistry","volume":"15 4","pages":"274 - 280"},"PeriodicalIF":0.6000,"publicationDate":"2021-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1134/S199075082104003X.pdf","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biochemistry (Moscow), Supplement Series B: Biomedical Chemistry","FirstCategoryId":"2","ListUrlMain":"https://link.springer.com/article/10.1134/S199075082104003X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 1

Abstract

Computer simulation has been used to identify peptides that mimic the natural target of the SARS-CoV-2 coronavirus spike (S) protein, the angiotensin-converting enzyme type 2 (ACE2) cell receptor. Based on the structure of the complex of the protein S receptor-binding domain (RBD) and ACE2, the design of chimeric molecules consisting of two 22–23-mer peptides linked to each other by disulfide bonds was carried out. The chimeric molecule X1 was a disulfide dimer, in which terminal cysteine residues in the precursor molecules h1 and h2 were connected by the S-S bond. In the chimeric molecule X2, the disulfide bond was located in the middle of each precursor peptide molecule. The precursors h1 and h2 mimic amino acid sequences of α1- and α2-helices of the ACE2 extracellular peptidase domain, respectively, keeping intact most of the amino acid residues involved in the interaction with RBD. The aim of the work was to evaluate the binding efficiency of chimeric molecules and their constituent peptides with RBD (particularly in dependence of the middle and terminal methods of fixing the initial peptides h1 and h2). The proposed polypeptides and chimeric molecules were synthesized by chemical methods, purified to 95–97% purity, and characterized by HPLC and MALDI-TOF mass spectrometry. Binding of these peptides to the SARS-CoV-2 RBD was evaluated by microthermophoresis with recombinant domains corresponding in sequence to the original Chinese (GenBank ID NC_045512.2) and the British (B. 1.1.7, GISAID EPI_ISL_683466) variants. The original RBD of the Chinese variant bound to three synthesized peptides: linear h2 and both chimeric variants. Chimeric peptides were also bound to the RBD of the British variant. The antiviral activity of the proposed peptides was evaluated in Vero cell line.

SARS-CoV-2受体结合域与ACE2细胞受体相互作用的肽抑制剂
计算机模拟已被用于识别模拟SARS-CoV-2冠状病毒刺突蛋白(S)自然靶标的肽,血管紧张素转换酶2型(ACE2)细胞受体。基于蛋白质S受体结合域(RBD)和ACE2复合物的结构,设计了由两个22-23-mer肽通过二硫键相互连接的嵌合分子。嵌合分子X1为二硫二聚体,其前体分子h1和h2的末端半胱氨酸残基通过S-S键连接。在嵌合分子X2中,二硫键位于每个前体肽分子的中间。前体h1和h2分别模拟ACE2胞外肽酶结构域α1-和α2-螺旋的氨基酸序列,保持了与RBD相互作用的大部分氨基酸残基的完整。这项工作的目的是评估嵌合分子及其组成肽与RBD的结合效率(特别是依赖于固定初始肽h1和h2的中间和末端方法)。采用化学方法合成多肽和嵌合分子,纯化纯度为95-97%,并采用HPLC和MALDI-TOF质谱法对其进行了表征。利用微热电泳技术评估这些肽与SARS-CoV-2 RBD的结合,重组结构域序列与原始中国(GenBank ID NC_045512.2)和英国(B. 1.1.7, GISAID EPI_ISL_683466)变体相对应。中国变体的原始RBD结合到三个合成肽:线性h2和两个嵌合变体。嵌合肽也与英国变异的RBD结合。在Vero细胞株中对所提多肽的抗病毒活性进行了评价。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.10
自引率
0.00%
发文量
31
期刊介绍: Biochemistry (Moscow), Supplement Series B: Biomedical Chemistry   covers all major aspects of biomedical chemistry and related areas, including proteomics and molecular biology of (patho)physiological processes, biochemistry, neurochemistry, immunochemistry and clinical chemistry, bioinformatics, gene therapy, drug design and delivery, biochemical pharmacology, introduction and advertisement of new (biochemical) methods into experimental and clinical medicine. The journal also publishes review articles. All issues of the journal usually contain solicited reviews.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信